Clinical trials
COVID-19 trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
108 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 52 |
| 2021 | 35 |
| 2022 | 15 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 62 |
| Unknown status | 26 |
| Terminated | 13 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Post Graduate Institute of Medical Education and Research, Chandigarh | 6 |
| Max Healthcare Insititute Limited | 5 |
| Aarogyam UK | 4 |
| Bharat Biotech International Limited | 3 |
| Cadila Pharnmaceuticals | 3 |
| Vicore Pharma AB | 3 |
| 101 Therapeutics | 2 |
| AstraZeneca | 2 |
| NMC Specialty Hospital | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 108 |
| Coronavirus Infections | 9 |
| Pneumonia | 6 |
| Severe Acute Respiratory Syndrome | 5 |
| Communicable Diseases | 3 |
| Cytokine Release Syndrome | 3 |
| Influenza, Human | 3 |
| Respiratory Distress Syndrome | 3 |
| Respiratory Tract Infections | 3 |
| Cardiovascular Diseases | 2 |
Trials
Showing 76 to 100 of 108. Each trial links to its page on Pharma Observatory.
8 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.